TY - JOUR
T1 - Antimalarial pantothenamide metabolites target acetyl-coenzyme A biosynthesis in Plasmodium falciparum
AU - Schalkwijk, Joost
AU - Allman, Erik L.
AU - Jansen, Patrick A.M.
AU - De Vries, Laura E.
AU - Verhoef, Julie M.J.
AU - Jackowski, Suzanne
AU - Botman, Peter N.M.
AU - Beuckens-Schortinghuis, Christien A.
AU - Koolen, Karin M.J.
AU - Bolscher, Judith M.
AU - Vos, Martijn W.
AU - Miller, Karen
AU - Reeves, Stacy A.
AU - Pett, Helmi
AU - Trevitt, Graham
AU - Wittlin, Sergio
AU - Scheurer, Christian
AU - Sax, Sibylle
AU - Fischli, Christoph
AU - Angulo-Barturen, Iñigo
AU - Jiménez-Diaz, Mariá Belén
AU - Josling, Gabrielle
AU - Kooij, Taco W.A.
AU - Bonnert, Roger
AU - Campo, Brice
AU - Blaauw, Richard H.
AU - Rutjes, Floris P.J.T.
AU - Sauerwein, Robert W.
AU - Llinás, Manuel
AU - Hermkens, Pedro H.H.
AU - Dechering, Koen J.
PY - 2019/9/18
Y1 - 2019/9/18
N2 - Malaria eradication is critically dependent on new therapeutics that target resistant Plasmodium parasites and block transmission of the disease. Here, we report that pantothenamide bioisosteres were active against blood-stage Plasmodium falciparum parasites and also blocked transmission of sexual stages to the mosquito vector. These compounds were resistant to degradation by serum pantetheinases, showed favorable pharmacokinetic properties, and cleared parasites in a humanized mouse model of P. falciparum infection. Metabolomics revealed that coenzyme A biosynthetic enzymes converted pantothenamides into coenzyme A analogs that interfered with parasite acetyl-coenzyme A anabolism. Resistant parasites generated in vitro showed mutations in acetyl-coenzyme A synthetase and acyl-coenzyme A synthetase 11. Introduction and reversion of these mutations in P. falciparum using CRISPR-Cas9 gene editing confirmed the roles of these enzymes in the sensitivity of the malaria parasites to pantothenamides. These pantothenamide compounds with a new mode of action may have potential as drugs against malaria parasites.
AB - Malaria eradication is critically dependent on new therapeutics that target resistant Plasmodium parasites and block transmission of the disease. Here, we report that pantothenamide bioisosteres were active against blood-stage Plasmodium falciparum parasites and also blocked transmission of sexual stages to the mosquito vector. These compounds were resistant to degradation by serum pantetheinases, showed favorable pharmacokinetic properties, and cleared parasites in a humanized mouse model of P. falciparum infection. Metabolomics revealed that coenzyme A biosynthetic enzymes converted pantothenamides into coenzyme A analogs that interfered with parasite acetyl-coenzyme A anabolism. Resistant parasites generated in vitro showed mutations in acetyl-coenzyme A synthetase and acyl-coenzyme A synthetase 11. Introduction and reversion of these mutations in P. falciparum using CRISPR-Cas9 gene editing confirmed the roles of these enzymes in the sensitivity of the malaria parasites to pantothenamides. These pantothenamide compounds with a new mode of action may have potential as drugs against malaria parasites.
U2 - 10.1126/scitranslmed.aas9917
DO - 10.1126/scitranslmed.aas9917
M3 - Article
C2 - 31534021
AN - SCOPUS:85072403566
VL - 11
JO - Science Translational Medicine
JF - Science Translational Medicine
SN - 1946-6234
IS - 510
M1 - eaas9917
ER -